Progyny, Inc. Common Stock
PGNYProgyny, Inc. (PGNY) is a healthcare company that specializes in fertility benefits management. It provides comprehensive fertility solutions and coverage options for employers and health plans, aiming to improve access to fertility treatments and support individuals and couples on their reproductive journey.
Company News
Progyny CFO Mark Livingston sold 8,275 shares (9.47% of his direct holdings) for $211,000 on May 20, 2026, as part of a pre-arranged Rule 10b5-1 trading plan adopted in August 2025. The sale is not considered a red flag as it was non-discretionary. Despite losing a major customer, Progyny's shares rose in Q2 after the company provided strong 2026...
Progyny's CEO Pete Anevski and CFO Mark Livingston will participate in a fireside chat at the BofA Securities 2026 Health Care Conference on May 12, 2026. The company reported record first quarter 2026 revenue of $328.5 million, reflecting strong demand for women's health and family building solutions.
Progyny, Inc. (Nasdaq: PGNY), a women's health and family building solutions company, announced it will report its Q1 2026 financial results on May 7, 2026, followed by a conference call. The company also announced the launch of the industry's first fully insured supplemental fertility plan for small employers, marking 10 years of operations in r...
Progyny, Inc. announced it will report its financial results for Q4 2025 and full year 2025 on February 26, 2026, after market close. The company will host a conference call at 4:45 p.m. ET to discuss results. A live webcast will be available on the company's investor relations website.
Progyny's CEO Peter Anevski purchased 79,500 shares worth approximately $1.9 million, increasing his direct ownership to 680,251 shares. The purchase signals confidence in the company's performance, which has seen 9% sales growth and near-100% customer retention.
